Alan Ashworth, PhD

Professor
Department of Medicine
+1 415 476-5876
Publications: 

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.

Gut

Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ

Structural basis for recruitment of BRCA2 by PALB2.

EMBO reports

Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Molecular cancer therapeutics

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ

Family history and risk of breast cancer: an analysis accounting for family structure.

Breast cancer research and treatment

Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

British journal of cancer

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ